Search

MORE NEWS
HEALTHCARE | Tony Chua, Singapore
Published: 07 Apr 11
1428 views


A*STAR scientists join forces with Servier to develop anti-cancer drugs

The partnership aim to develop drugs restricting the growth of tumor-initiating cells in breast cancer.

A*STAR’s Singapore Immunology Network (SIgN) has inked a Research Collaboration Agreement (RCA) with Servier, the second largest French pharmaceutical company in the world. The collaboration aims to develop anti-cancer drugs to suppress tumor-initiating cells (TICs), often called “cancer stem cells”. By targeting TICs, scientists hope to be able to prevent relapse and metastatic outgrowth in cancer patients.

Under this three-year partnership, SIgN and Servier aim to develop drugs directed at restricting the growth of TICs in breast cancer - the most common cancer in women all over the world, and also in Singapore with about 1,100 new cases diagnosed each year. Scientists at SIgN, with their expertise in tumour immunology and therapeutic antibodies, will be able to isolate TIC-specific human monoclonal antibodies, and with the help of Servier, develop them into anti-cancer drugs, accordinbg to an A*STAR report.

As Associate Professor Jean-Pierre Abastado, Principal Investigator of SIgN that will head the lab for this SIgN-Servier collaboration said, “Scientists and clinicians have been trying to understand why cancer relapse occurs in spite of the removal of the primary tumor. Basic research conducted at SIgN has shown that cancer relapse could potentially be avoided by controlling TICs. Our task at hand is to discover the monoclonal antibodies that will target these TICs.”

Dr. Emmanuel Canet, MD PhD, Head of Research & Development at Servier added, “This partnership exemplifies our vision to collaborate with leading scientists worldwide to discover and develop innovative medicines in the field of cancer where the medical need is still huge. We have been very impressed by the quality of the research work done at the Singapore Immunology Network (SIgN), which we believe is one of the best such institutes in the world.”

“Elimination of tumour initiating cells represents a major challenge in oncology. The aim of this collaboration is to develop an innovative approach to identify membrane neo-antigens specifically expressed by breast cancer stem cells. There is a great therapeutic potential since therapeutic antibodies against these neo-antigens could be used to control the residual disease by eliminating cancer stem cells persisting after conventional therapies", said Dr Stéphane Depil, MD PhD, director of Oncology Research & Development Unit at Servier.”

Prof Paola Castagnoli, Scientific Director of SIgN added “This project is supported by a joint lab between Servier and us and it will be located within SIgN. This is a strategy that we have already successfully developed last year with another company, in the field of Infectious Diseases. Pharma companies are very interested to develop new projects where they can find both an excellent scientific environment, together with unique technology platforms such as our fully human Monoclonal Platform and our Immuno-monitoring platform that can speed up the process of drug discovery.”

Chairman of SIgN, Prof Philippe Kourilsky commented, “I believe that this partnership with Servier will soon lead to the discovery of novel cancer drugs that will effectively control cancer relapse, enhancing the survival of cancer patients. I’m particularly delighted that this work stems from the results of basic research in Tumour Immunology conducted at SIgN. This partnership with Servier was made possible thanks to the powerful human monoclonal antibody platform that we have developed. This is an excellent example of how public research institutes and private companies can leverage on each other’s strength to come up with innovative solutions to address pressing medical needs such as fighting cancer effectively.”



Sign up for our newsletter

 

Do you know more about this story? Contact us anonymously through this link.

Click here to learn about advertising, content sponsorship, events & rountables, custom media solutions, whitepaper writing, sales leads or eDM opportunities with us.

To get a media kit and information on advertising or sponsoring click here.

Tags: A*STAR Servier, A*STAR Servier research, A*STAR Servier cancer drug research

LATEST HEALTHCARE JOBS »
PRINT ISSUE »

Subscribe Now
As goes Hong Kong, so goes Singapore?

70 views

Office property shows no signs of a slowdown

21 views

Where did the consumer go?

34 views

MOST READ EXCLUSIVES

10 Asian airlines to hate for excessive late arrivals in December

10 Asian airlines to hate for excessive late arrivals in December

Chinese airlines dominated the list.

by STAFF REPORTER
14 Jan 2014 | 10143 views
 

Singapore's top 8 reunion dinner hotel restaurants

Singapore\'s top 8 reunion dinner hotel restaurants

Gallop into the Year of the Horse with these top picks.

by KRISANA GALLEZO
13 Jan 2014 | 26042 views

All you need to know about securing the Cloud

All you need to know about securing the Cloud

The remedy of a private cloud attack is around $9 million, studies show.

by KRISANA GALLEZO
13 Jan 2014 | 453 views
 

UOB, Dairy Farm unveil 'Delight' credit and debit cards

UOB, Dairy Farm unveil \'Delight\' credit and debit cards

Targets to reward household spenders.

by STAFF REPORTER
10 Jan 2014 | 966 views

What you didn't know about iProperty.com's awards for developers

What you didn\'t know about iProperty.com\'s awards for developers

And the challenges behind the awards.

by STAFF REPORTER
9 Jan 2014 | 626 views
 

Find out how Singapore’s Nevigate challenges telco giants through IP innovation

Find out how Singapore’s Nevigate challenges telco giants through IP innovation

Its revenue is pegged to hit $3.5m.

by CARMINA JARIEL
9 Jan 2014 | 570 views

Will Singapore economy kick strongly in the year of the wooden horse?

Will Singapore economy kick strongly in the year of the wooden horse?

Analysts have mixed predictions.

by KAREN MESINA
8 Jan 2014 | 1377 views
 

6 in 10 Australian corporates eye raising equity in 2014

6 in 10 Australian corporates eye raising equity in 2014

Are better days finally coming?

by KAREN MESINA
20 Dec 2013 | 1971 views

Here are the 10 hottest restaurants in Singapore this year

Here are the 10 hottest restaurants in Singapore this year

Have you tried them all?

by STAFF REPORTER
19 Dec 2013 | 27391 views
 

What should Singapore banks brace themselves for in 2014?

What should Singapore banks brace themselves for in 2014?

Mortgages predicted to disappoint.

by STAFF REPORTER
18 Dec 2013 | 2978 views
close Don't Show Again

STAY INFORMED! Get our free weekly newsletter